KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Thermo Fisher Scientific (TMO) Gains from Investment Securities (2016 - 2026)

Thermo Fisher Scientific filings provide 18 years of Gains from Investment Securities readings, the most recent being -$88.0 million for Q1 2026.

  • On a quarterly basis, Gains from Investment Securities rose 34.81% to -$88.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$408.0 million, a 353.33% decrease, with the full-year FY2025 number at -$455.0 million, down 5587.5% from a year prior.
  • Gains from Investment Securities hit -$88.0 million in Q1 2026 for Thermo Fisher Scientific, up from -$435.0 million in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $408.0 million in Q4 2023 to a low of -$470.0 million in Q4 2022.
  • Median Gains from Investment Securities over the past 5 years was -$88.0 million (2026), compared with a mean of -$66.7 million.
  • The widest YoY moves for Gains from Investment Securities: up 204.17% in 2022, down 23600.0% in 2022.
  • Thermo Fisher Scientific's Gains from Investment Securities stood at -$470.0 million in 2022, then skyrocketed by 186.81% to $408.0 million in 2023, then plummeted by 39.71% to $246.0 million in 2024, then crashed by 276.83% to -$435.0 million in 2025, then skyrocketed by 79.77% to -$88.0 million in 2026.
  • The last three reported values for Gains from Investment Securities were -$88.0 million (Q1 2026), -$435.0 million (Q4 2025), and $178.0 million (Q3 2025) per Business Quant data.